(S1 (S (NP (NP (NN NF-kappaB)) (CC and) (NP (NN PKC-LRB-s-RRB-))) (VP (VBP Mediate) (NP (JJ Human) (NN MDM) (NN Survival)) (PP (IN in) (NN Response) (TO to) (NP (NN M-CSF) (NN Stimulation))))))
(S1 (S (SBAR (IN Since) (S (NP (NP (NN PKC)) (CC and) (NP (NN NF-kappaB))) (VP (VBP are) (ADJP (JJ critical) (PP (IN in) (NP (NP (NN cell) (NN survival) (-LRB- -LSB-) (CD 37) (-RRB- -RSB-)) (, ,) (FRAG (-LRB- -LSB-) (NP (CD 38)) (-RRB- -RSB-)))))))) (, ,) (NP (PRP we)) (VP (VBD hypothesized) (SBAR (IN that) (S (NP (NN M-CSF)) (VP (VBD promoted) (NP (NN cell) (NN survival)) (PP (IN through) (NP (NN PKC))) (PP (IN in) (NP (JJ human) (NNS MDMs))))))) (. .)))
(S1 (S (S (S (VP (TO To) (VP (VB detect) (NP (NN apoptosis))))) (, ,) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (VBN cleaved) (NN caspase-3)) (, ,) (NP (NP (DT a) (NN marker)) (PP (IN of) (NP (NN apoptosis)))) (, ,)))) (VP (VBD was) (VP (VBN analyzed) (PP (IN in) (NP (NP (DT the) (NP (NN presence)) (CC or) (NP (NN absence))) (PP (IN of) (NP (NP (NN M-CSF)) (CC and) (NP (NN PKC) (NNS inhibitors))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (NNS MDMs)) (VP (VP (VBN pretreated) (PP (IN with) (NP (NP (NN PKC) (NNS inhibitors)) (PRN (-LRB- -LRB-) (NP (NP (NN Ro-31-8220)) (, ,) (NP (NN Go-6976)) (, ,) (CC or) (NP (NN BAPTA/AM))) (-RRB- -RRB-))))) (CC and) (VP (VBN stimulated) (PP (IN with) (NP (NN M-CSF))))))) (, ,) (NP (VBN cleaved) (NN caspase-3)) (VP (VBD was) (VP (VBN elevated) (PP (TO to) (NP (NP (NNS levels)) (PP (IN of) (NP (NP (NNS cells)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NN vehicle)) (ADVP (RB alone))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 3A)) (-RRB- -RRB-)))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NNS cells)) (VP (VBN incubated) (PP (IN with) (NP (NP (NN M-CSF)) (CC and) (NP (NN vehicle)))))) (VP (VBD had) (NP (ADJP (RBR less) (VBN cleaved)) (NN caspase-3)) (PP (IN than) (NP (NP (NNS cells)) (VP (VBN incubated) (PP (IN with) (NP (NP (NP (NN vehicle)) (ADVP (RB alone))) (CC or) (NP (NN M-CSF)))) (PP (IN with) (NP (NN PKC) (NNS inhibitors)))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS data)) (VP (VBD supported) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (JJ M-CSF-induced) (NN NF-kappaB) (NN activity)) (VP (VBD was) (VP (VBN regulated) (PP (IN by) (NP (JJ conventional) (NNS PKCs))) (, ,) (PP (RB not) (NP (JJ novel) (NNS PKCs)))))))))) (. .)))
(S1 (S (S (S (VP (TO To) (VP (VB confirm) (SBAR (IN that) (S (NP (NN PKC) (NN inhibition)) (VP (VBD decreased) (NP (NN cell) (NN survival)))))))) (, ,) (NP (NNS cells)) (VP (VBD were) (VP (VP (VBN treated) (PP (IN with) (NP (NN M-CSF))) (PP (IN in) (NP (NP (DT the) (NP (NN absence)) (CC or) (NP (NN presence))) (PP (IN of) (NP (NN PKC) (NNS inhibitors)))))) (CC and) (RB then) (ADVP (RB also)) (VP (VBN examined) (PP (IN for) (NP (NN apoptosis))) (PP (IN by) (NP (NN Annexin) (NN V/PI) (NN staining))))))) (. .)))
(S1 (S (S (NP (NP (NN PKC) (NNS inhibitors)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN M-CSF)))))) (VP (VBD reduced) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NN Annexin) (NN V/PI) (JJ negative) (NNS MDMs)))) (PP (VBN compared) (PP (TO to) (NP (NP (NNS cells)) (VP (VBN treated) (PP (IN with) (NP (NN M-CSF))) (ADVP (ADVP (RB alone)) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 3B)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS observations)) (ADVP (RB further)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NN MDM) (NN survival)) (VP (VP (VBZ is) (VP (VBN promoted) (PP (IN by) (NP (NN M-CSF))))) (CC and) (ADVP (RB critically)) (VP (VBZ involves) (NP (NP (JJ conventional) (NNS PKCs)) (CC and) (NP (NN NF-kappaB) (NN activity))))))))) (. .)))
